Effect of Mesalazine Treatment on GI Symptoms and Rectal Biomarkers of Immune Activity in IBS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Alimentary Pharmacology & Therapeutics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity
Aliment. Pharmacol. Ther. 2022 Sep 01;56(6)968-979, V Castro Tejera, L Öhman, L Aabakken, B Fellström, T Hausken, Ø Hovde, JP Hreinsson, G Lindberg, P Venge, M Simrén, H TörnblomFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.